AbbVie Inc (ABBV)
Working capital turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 56,334,000 | 55,533,000 | 55,000,000 | 54,403,000 | 54,318,000 | 55,138,000 | 56,023,000 | 56,741,000 | 58,054,000 | 57,819,000 | 57,349,000 | 56,725,000 | 56,197,000 | 55,169,000 | 53,729,000 | 50,195,000 | 45,804,000 | 40,650,000 | 36,227,000 | 34,057,000 |
| Total current assets | US$ in thousands | 25,582,000 | 27,785,000 | 33,816,000 | 38,871,000 | 33,002,000 | 33,224,000 | 28,852,000 | 26,488,000 | 28,463,000 | 30,364,000 | 29,100,000 | 26,509,000 | 27,928,000 | 28,957,000 | 25,999,000 | 26,569,000 | 24,173,000 | 23,009,000 | 21,256,000 | 51,758,000 |
| Total current liabilities | US$ in thousands | 38,749,000 | 43,062,000 | 41,915,000 | 41,522,000 | 37,841,000 | 34,773,000 | 32,239,000 | 27,590,000 | 29,538,000 | 32,712,000 | 34,473,000 | 32,521,000 | 35,194,000 | 28,533,000 | 28,684,000 | 31,951,000 | 28,661,000 | 24,181,000 | 24,646,000 | 16,471,000 |
| Working capital turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | 130.12 | — | — | — | — | — | 0.97 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $56,334,000K ÷ ($25,582,000K – $38,749,000K)
= —
Working capital turnover is a financial ratio that measures how efficiently a company is using its working capital to generate revenue. A higher working capital turnover indicates a more efficient use of working capital.
According to the data provided, AbbVie Inc had a working capital turnover of 0.97 as of March 31, 2020. This figure suggests that for every dollar of working capital invested, AbbVie generated $0.97 in revenue during that period.
The subsequent data points are not available (denoted by "\u2014"), except for a significant spike in the working capital turnover ratio to 130.12 as of September 30, 2021. This unusually high ratio could indicate a potential anomaly in the data or a particular event impacting the company's working capital efficiency.
Without additional data points, it is challenging to assess the trend or make meaningful comparisons over time. Further insights would be needed to fully evaluate AbbVie's working capital turnover and its implications for the company's financial performance and efficiency in managing its working capital.
Peer comparison
Dec 31, 2024